NKG2D downregulation in cancer patients is mediated by cytokines such as TGFβ and IL‐10, as well as immunosuppressive molecules like prostaglandin E2 (PGE2), vascular endothelial growth factor (VEGF), nitric oxide synthase (NOS), and reactive oxygen species. This evidence concerns the gene TGFB1 and cancer.